Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
Holding DE:4AB?
Track your performance easily
4AB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€125.50 - €192.50
Previous Close€166.12
Volume154.00
Average Volume (3M)567.00
Market Cap
€289.47B
Enterprise Value€349.42B
Total Cash (Recent Filing)$7.29B
Total Debt (Recent Filing)$71.08B
Price to Earnings (P/E)62.9
Beta0.02
Next Earnings
Jan 29, 2025EPS Estimate
€2.79Next Dividend Ex-Date
Jan 15, 2025Dividend Yield3.11%
Share Statistics
EPS (TTM)2.64
Shares Outstanding1,767,140,323
10 Day Avg. Volume1,038
30 Day Avg. Volume567
Standard Deviation0.07
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)48.72
Price to Sales (P/S)6.35
Price to Cash Flow (P/CF)16.20
P/FCF Ratio15.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.29
Enterprise Value/Gross Profit10.31
Enterprise Value/Ebitda19.20
Forecast
1Y Price Target
€197.41Price Target Upside19.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
AbbVie News
Bulls Say, Bears Say
Bulls Say
Earnings GrowthABBV shares and their differentiated EPS growth profile are still favored as it accelerates on the back of the traditional drivers like Skyrizi and Rinvoq.
Guidance And PerformanceAbbVie reported solid 3Q results driven by Skyrizi/Rinvoq and oncology portfolio beats, and raised 2024 revenue guidance to $56B.
Market PositionABBV is a dominant player in the global aesthetics market.
Bears Say
Clinical Trials FailureAbbVie disclosed that both of its registrational studies (EMPOWER 1&2) of emraclidine for schizophrenia failed to meet their primary endpoints.
Financial Guidance And Market ChallengesThe company lowered 2024 aesthetics guidance to $5.5bn from $5.7bn, reflecting challenges such as Juvederm's vulnerability to macroeconomic weakness due to its higher price point.
Sales Erosion And Patent ExpiryContinued headwinds of Humira patent expiry are expected to create a difficult near-term period for the company, coupled with the downside risk from lower Humira sales and loss of exclusivity in the US.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
22.02% Mutual Funds
5.11% Other Institutional Investors
51.71% Public Companies and
Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €125.50 and its highest was €192.50 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jan 29, 2025 which is in 77 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 30, 2024. The company reported €2.817 earnings per share for the quarter, beating the consensus estimate of €2.742 by €0.075.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.54 which represents an annual dividend yield of 3.11%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is €2.79.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,140,400 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.817 in its last earnings report, beating expectations of €2.742. Following the earnings report the stock price went up 4.067%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 233M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€197.41 (19.08% Upside)
€197.41 (19.08% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 94%
Sector Average 73%
Sector Average 73%
News Sentiment
Bearish
Bullish news 40%
Bearish news 60%
Bearish news 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.46%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Earnings Call
Q3 2024
0:00 / 0:00
---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Month Forecast
Average Price Target
€197.41
▲(19.08% Upside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
34/39 ratings generated profit
1 Year Average Return
+21.23%
assigned a buy rating 21 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 87.18% of your transactions generating a profit, with an average return of +21.23% per trade.
---